ENLV

ENLV

Enlivex Ltd.

0.25 USD

Last updated Oct 13, 00:00 UTC

Yesterday HIGH

$0.28

Yesterday LOW

$0.22

52w HIGH

$27.15

52w LOW

$0.22

EPS

1.51

PE

0.17

Next Earnings

Oct 23, 2026

Overview News Government Trades Fundamentals

Enlivex Ltd. stock is down -73.94% since 30 days ago. The next earnings date is Oct 23, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30.77% of the previous 12 October’s closed higher than September.

Webmaster

Thu Jul 9, 2026

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk

Tue Jul 7, 2026

Enlivex shares are trading lower after the company announced a 1-for-15 reverse split.
Benzinga Newsdesk

Tue Jul 7, 2026

Enlivex Effects 1-for-15 Reverse Stock Split July 9, 2026
Benzinga Newsdesk

Mon Jun 22, 2026

Enlivex Holds 79.569B RAIN Token With Total Value Of ~$1.14B

Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company")), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of June 20, 2026,
Benzinga Newsdesk

Mon Jun 15, 2026

Enlivex Receives Australian Patent Entitled 'Therapeutic Apoptotic Cells For Treatment Of Osteoarthritis'

The patent will provide Enlivex with added intellectual property protection in Australia through at least 2040 with claims covering methods of using Allocetra™ to treat subjects with osteoarthritis. With this
Benzinga Newsdesk

Mon Jun 1, 2026

Enlivex To Feature Extended 3-Month And 6-Months Clinical Data In Knee Osteoarthritis Phase Iia Trial At EULAR European Congress Of Rheumatology

The data were selected for an oral podium presentation at EULAR and will be presented by Prof. Philip Conaghan, a globally recognized key opinion leader in osteoarthritisNes-Ziona, Israel, June 01, 2026 (GLOBE NEWSWIRE)
Benzinga Newsdesk

Mon May 18, 2026

EnLivex Doses First Patient In Its Phase 2b Clinical Trial Of Allocetra For Treatment Of Patients With Moderate-to-Severe Age-Related Symptomatic Primary Knee Osteoarthritis

The global, multicenter, randomized, double-blind, placebo-controlled Phase 2b clinical trial is designed to evaluate the efficacy and safety of intra-articular injections of Allocetra™ in patients with
Benzinga Newsdesk

Fri May 15, 2026

Enlivex Receives Nasdaq Noncompliance Notice
Benzinga Newsdesk

Tue Apr 28, 2026

Enlivex Treasury Holdings Of RAIN Tokens Reaches 78,819,756,062 Tokens Valued At $567M
Benzinga Newsdesk

Tue Apr 21, 2026

Enlivex Files Prospectus Related To Resale Of Up To 23.33M Shares By Selling Shareholder

SEC.

CBRS $146.66 USD

SCHW $97.10 USD

KTOS $41.65 USD

SNDK $1,487.30 USD

DRAM DRAM $54.70 USD

USAR $11.83 USD

SBUX $92.33 USD

MSFT $541.13 USD